Stayble Therapeutics Investor Relations Material
Latest events
CEO Sitdown with Kalqyl Q4 2023
Stayble Therapeutics
Q1 2025
21 May, 2025
Q4 2024
25 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Stayble Therapeutics
Access all reports
Stayble Therapeutics is a clinical-stage biotechnology company developing non-surgical treatments for chronic disc-related back pain. Its lead candidate targets degenerative disc disease using injectable therapeutics. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Nasdaq First North Growth Market.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
STABL
Country
🇸🇪 Sweden